LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung

    European Respiratory Journal, 2013.

    Cited by: 98|Bibtex|Views3|

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments